Is High Dose Aspirin Needed in Kawasaki Disease (KD)? Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with KD? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial https://t.co/vThkP4AH6x

Recent Medscape Physician Compensation Report 2025, MD Salaries dropped by: Dermatology: -11% Neurology: -6% Urology: -6% Plastic surgery: -4% Cardiology: -4% Ophthalmology: -4% Gastroenterology: -3% Rheumatology: -3% https://t.co/WZDM7XxeEU https://t.co/PhRlHaXsMb

The IL-17A inhibitor, secukinumab, is in late-stage development forthe treatment of giant cell arteritis and polymyalgia rheumatica. https://t.co/JzzqS7bSjd https://t.co/9Qm0YsJmOL

FDA reports higher rate of allergic/hypersensitivity type reactions w/ certainlots of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) ; these have voluntarily withdrawn by the manufacturers https://t.co/j0yVBodLtW https://t.co/k7s4LtLnyu

Full read state of the art review of treatments for Axial Spondyloarthritis Concluding unmet needs: -Suboptimal Tx Response - Limited Drug Options - No Biomarkers - Extra-Axial Dz - Non-Inflammatory Pain https://t.co/K3oqRCgTCP https://t.co/rkX2givwF8

Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 developed KOA. HRs for incident KOA were 0.84 (0.76-0.92), 0.81 (0.71-0.90), and 0.74 (0.64-0.85) if walking ~5000, ~7000, & ≥8000 steps/d, respectively https://t.co/fwVRRsoQYr

Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://t.co/ZJmZWdxo5Q https://t.co/EMYC1cnsXP

AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in 5 yrs of Dx best by iCCP3, RFIgA, RFIgM; and 104 proteins differentially expressed & gene analyses showed 21 pathways enriched ≤5 years of Dx. https://t.co/EWwpvrduJz

Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/OmlLpNXRmE

The IL-17A inhibitor, secukinumab, is in late-stage development forthe treatment of giant cell arteritis and polymyalgia rheumatica. https://t.co/JzzqS7bSjd https://t.co/PNvHdJsKlL

Should Lupus Nephritis Receive PJP Prophylaxis? A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and https://t.co/zzRIVG0Sq3

#JIA #biologics and #tsDMARDs: Are all patients getting the same access? MDTs, share your insights on on-label and off-label prescribing and help improve future care. 💬 Take the survey by 15 April: https://t.co/vC2Pv5vmH4 https://t.co/rRM5rH0QQl